North America Anticoagulant Reversal Drugs Market Size, 2027

North America Anticoagulant Reversal Drugs Market By Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Online Pharmacy), By Product Type (Idarucizumab, Andexanet Alfa, Prothrombin Complex Concentrates, Phytonadione, Protamine and Others), By Country, Growth Potential, Industry Analysis Report and Forecast, 2021 - 2027

Published Date: June-2021 | Number of Pages: 67 | Format: PDF | Report ID: KBV-14969

Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support


Get in-depth analysis of the COVID-19 impact on the North America Anticoagulant Reversal Drugs Market

Market Report Description

The North America Anticoagulant Reversal Drugs Market would witness market growth of 12.5% CAGR during the forecast period (2021-2027). Doctors recommend Anticoagulant reversal drugs when anticoagulant therapy of a patient should be reversed or neutralized.

It mostly occurs when there are bleeding complications and, in such cases, an overdose of anticoagulant drug therapy is given. Oral anticoagulants are used to treat blood-related disorders. It is extremely beneficial in reducing the risk of thromboembolism in AFib patients. The dose of anticoagulants can cause bleeding in AFib patients and they are suggested to take anticoagulant reversal drugs that can prevent excessive bleeding.

Bleeding is sometimes a complicated condition for all anticoagulant therapy. Sometimes, it can lead to chronic debilitating conditions or even death. The possibility of hemorrhage is likely to be associated with the intake of anticoagulation. The risk of bleeding may also be increased with antiplatelet medication, cyclooxygenase type-2 inhibitors, and non-steroidal anti-inflammatory agent treatment. When bleeding is excess and it becomes life-threatening, then anticoagulant reversal drugs are given. It is also used when anticoagulant activity needs to be reversed prior to any surgery. The risk of bleeding versus thromboembolism must be evaluated for each specific patient.

According to the “Global Health and Wellness Report”, in the USA more than 40% of the adult population were suffering from cardiovascular disease in 2018. Moreover, it is also estimated by the heart disease and Stroke Statistics 2019 that 1 out of 3 individuals in the United States is vulnerable to lifetime risk of atrial fibrillation. Thus, the increasing number of cardiovascular diseases is expected to be a big burden on the health care system. It will act as a major factor for the growing demand for anticoagulant reversal drugs in this region and will drive the growth of the market in the coming years. Manufacturers of the anticoagulant reversal drugs market are well aware of the increasing demand and thus navigating their research & development to increase the development of these drugs. These aspects would boost the growth of the market in the region.

The US market dominated the North America Retail Pharmacy Market by Country in 2020, and would continue to be a dominant market till 2027. The Canada market is experiencing a CAGR of 14.9% during (2021-2027). Additionally, The Mexico market would witness a CAGR of 13.9% during (2021-2027).

Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. Based on Product Type, the market is segmented into Idarucizumab, Andexanet Alfa, Prothrombin Complex Concentrates, Phytonadione, Protamine and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

Free Valuable Insights: The Global Anticoagulant Reversal Drugs Market is Estimated to Reach USD 1.6 Billion by 2027 at a CAGR of 13.3%

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Boehringer Ingelheim International GmbH, CSL Limited, Bausch Health Companies, Inc., Octapharma AG, Pfizer, Inc., Fresenius SE & Co. KGaA, Alexion Pharmaceuticals, Inc. (Portola Pharmaceuticals), Dr. Reddy’s Laboratories Ltd., AMAG Pharmaceuticals, Inc. (Covis Pharma), and Alps Pharmaceutical Ind. Co., Ltd.

Scope of the Study

Market Segments Covered in the Report:

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Product Type

  • Idarucizumab
  • Andexanet Alfa
  • Prothrombin Complex Concentrates
  • Phytonadione
  • Protamine
  • Others

By Country

  • US
  • Canada
  • Mexico
  • Rest of North America

Key Market Players

List of Companies Profiled in the Report:

  • Boehringer Ingelheim International GmbH
  • CSL Limited
  • Bausch Health Companies, Inc.
  • Octapharma AG
  • Pfizer, Inc.
  • Fresenius SE & Co. KGaA
  • Alexion Pharmaceuticals, Inc. (Portola Pharmaceuticals)
  • Dr. Reddy’s Laboratories Ltd.
  • AMAG Pharmaceuticals, Inc. (Covis Pharma)
  • Alps Pharmaceutical Ind. Co., Ltd.

Unique Offerings from KBV Research

  • Exhaustive coverage
  • The highest number of market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Anticoagulant Reversal Drugs Market Related Reports:

Global Market

Europe Market

Asia Pacific Market

LAMEA Market

Purchase Report


Special Pricing & Discounts

  • Buy Sections of This Report
  • Buy Country Level Reports
  • Request for Historical Data
  • Discounts Available for Start-Ups & Universities